- Home
- WH vs ARWR Comparison
WH vs ARWR Comparison
Compare WH & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WH
- ARWR
- Stock Information
- Founded
- WH 2017
- ARWR 2003
- Country
- WH United States
- ARWR United States
- Employees
- WH N/A
- ARWR N/A
- Industry
- WH Hotels/Resorts
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- WH Consumer Discretionary
- ARWR Health Care
- Exchange
- WH Nasdaq
- ARWR Nasdaq
- Market Cap
- WH 5.8B
- ARWR 4.9B
- IPO Year
- WH N/A
- ARWR 1993
- Fundamental
- Price
- WH $78.41
- ARWR $36.84
- Analyst Decision
- WH Strong Buy
- ARWR Strong Buy
- Analyst Count
- WH 11
- ARWR 8
- Target Price
- WH $104.98
- ARWR $47.75
- AVG Volume (30 Days)
- WH 774.3K
- ARWR 2.0M
- Earning Date
- WH 10-22-2025
- ARWR 11-25-2025
- Dividend Yield
- WH 2.10%
- ARWR N/A
- EPS Growth
- WH 38.05
- ARWR N/A
- EPS
- WH 4.27
- ARWR N/A
- Revenue
- WH $1,448,000,000.00
- ARWR $572,976,000.00
- Revenue This Year
- WH $7.83
- ARWR $21,421.26
- Revenue Next Year
- WH $5.94
- ARWR N/A
- P/E Ratio
- WH $18.33
- ARWR N/A
- Revenue Growth
- WH 4.32
- ARWR 2816.20
- 52 Week Low
- WH $75.29
- ARWR $9.57
- 52 Week High
- WH $113.07
- ARWR $40.29
- Technical
- Relative Strength Index (RSI)
- WH 40.44
- ARWR 62.26
- Support Level
- WH $77.05
- ARWR $34.61
- Resistance Level
- WH $79.32
- ARWR $40.29
- Average True Range (ATR)
- WH 1.87
- ARWR 1.67
- MACD
- WH 0.01
- ARWR -0.21
- Stochastic Oscillator
- WH 47.78
- ARWR 48.82
About WH Wyndham Hotels & Resorts Inc.
As of June 30, 2025, Wyndham Hotels & Resorts operates 846,700 rooms across more than 20 brands predominantly in the economy and midscale segments. Super 8 is the largest brand, representing around 18% of all rooms, with Days Inn (13%) and Ramada (14%) the next two largest brands, as of the end of 2024. During the past several years, the company has expanded its extended stay/lifestyle brands, which appeal to travelers seeking to experience the local culture of a given location. The company closed its La Quinta acquisition in the second quarter of 2018, adding around 90,000 rooms at the time the deal closed. Wyndham launched a new extended stay economy scale segment concept, ECHO, in the spring of 2022. The United States represents 56% of total rooms, as of the end of 2024.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.